Skip to main content

Table 1 Patient characteristics

From: 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

  All Patients
(n = 386)
Colorectal cancer
(n = 161)
Lung cancer
(n = 140)
Ovarian cancer
(n = 45)
Breast cancer
(n = 40)
Age,n (%) 65 years 178 (46.1) 66 (41.0) 92 (65.7) 9 (20.0) 11 (27.5)
    <  65 years 208 (53.9) 95 (59.0) 48 (34.3) 36 (80.0) 29 (72.5)
Median (range) 64 (26–84) 62 (30–79) 68 (39–84) 57 (26–76) 54.5 (37–73)
Sex (%) Female 185 (47.9) 71 (44.1) 29 (20.7) 45 (100.0) 40 (100.0)
Motion sickness (%) Yes 59 (15.3) 22 (13.7) 12 (8.6) 13 (28.9) 12 (30.0)
Drinking habit (%) Yes 203 (52.6) 79 (49.1) 83 (59.3) 23 (51.1) 18 (45.0)
Smoking habit (%) Yes 150 (38.9) 56 (34.8) 88 (62.9) 2 (4.4) 4 (10.0)
Pregnancy associated vomiting (%) Yes 95 (51.4) 34 (47.9) 20 (69.0) 20 (44.4) 21 (52.5)
Palonosetoron (%) 153 (39.6) 132 (82.0) 9 (6.4) 1 (2.2) 11 (27.5)
Regimen      
 CBDCA (AUC5) + ETP 34 (8.8) 34 (24.3)
 CBDCA+PTX 103 (26.7) 58 (41.4) 45 (100.0)
 CBDCA (AUC5) 20 2 18
 CBDCA (AUC6) 83 56 27
 CBDCA+PEM 48 (12.4) 48 (34.3)  
 CBDCA (AUC5) 11 11
 CBDCA (AUC6) 37 37
 DTX + CPA 40 (10.4) 40 (100.0)
 FOLFOX 79 (20.5) 79 (49.1)
 FOLFIRI 4 (1.0) 4 (2.5)
 CAPOX 78 (20.2) 78 (48.4)
  1. CBDCA Carboplatin, ETP Etoposide, PTX Paclitaxel, PEM Pemetrexed, CPA Cyclophosphamide, DTX Docetaxel, FOLFOX oxaliplatin with fluorouracil and folinic acid, FOLFIRI Irinotecan with fluorouracil and folinic acid, CAPOX Capecitabine plus oxaliplatin therapy